stoxline Quote Chart Rank Option Currency Glossary
  
Ultragenyx Pharmaceutical Inc. (RARE)
33.25  1.31 (4.1%)    11-11 16:00
Open: 31.7
High: 33.27
Volume: 1,157,615
  
Pre. Close: 31.94
Low: 31.5
Market Cap: 3,202(M)
Technical analysis
2025-11-11 4:49:44 PM
Short term     
Mid term     
Targets 6-month :  41.98 1-year :  49.04
Resists First :  35.95 Second :  41.98
Pivot price 33.28
Supports First :  31.38 Second :  28.56
MAs MA(5) :  31.72 MA(20) :  33.39
MA(100) :  31.18 MA(250) :  36.77
MACD MACD :  0.1 Signal :  0.4
%K %D K(14,3) :  45.7 D(3) :  38.7
RSI RSI(14): 53.6
52-week High :  50.47 Low :  25.8
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ RARE ] has closed above bottom band by 49.3%. Bollinger Bands are 5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 33.33 - 33.49 33.49 - 33.63
Low: 31.12 - 31.3 31.3 - 31.46
Close: 32.94 - 33.25 33.25 - 33.53
Company Description

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Headline News

Tue, 11 Nov 2025
Ultragenyx gets $400 million cash infusion, reports 15% rise in sales - The Press Democrat

Tue, 11 Nov 2025
Fox Run Management L.L.C. Invests $607,000 in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat

Mon, 10 Nov 2025
Morgan Stanley Reaffirms “Buy” Rating on Ultragenyx Pharmaceutical (RARE) with $55 PT - Insider Monkey

Sat, 08 Nov 2025
Ultragenyx Pharmaceutical (RARE): Exploring Valuation Gaps and Analyst Targets - Sahm

Sat, 08 Nov 2025
Ultragenyx Pharmaceutical (RARE): Exploring Valuation Gaps and Analyst Targets - simplywall.st

Thu, 06 Nov 2025
Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Lowered to $75.00 at TD Cowen - MarketBeat

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 96 (M)
Shares Float 93 (M)
Held by Insiders 3.1 (%)
Held by Institutions 100.8 (%)
Shares Short 8,690 (K)
Shares Short P.Month 7,950 (K)
Stock Financials
EPS -5.49
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.57
Profit Margin -87.4 %
Operating Margin -64.9 %
Return on Assets (ttm) -21.6 %
Return on Equity (ttm) -180.5 %
Qtrly Rev. Growth 13.1 %
Gross Profit (p.s.) -1.75
Sales Per Share 6.33
EBITDA (p.s.) -4.88
Qtrly Earnings Growth 0 %
Operating Cash Flow -421 (M)
Levered Free Cash Flow -206 (M)
Stock Valuations
PE Ratio -6.07
PEG Ratio 0
Price to Book value 21.17
Price to Sales 5.25
Price to Cash Flow -7.61
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android